AstraZeneca Results Presentation Deck
BioPharmaceuticals: Respiratory & Immunology
Recovery continued, but offset by Q1 2020 stocking effect
Respiratory down 4% from
$m high stocking base in 2020
2,000
1,500
1,000
500 -
Q1 2018
Q2 2018
Q3 2018
Q4 2018
Q1 2019
Q2 2019
Q3 2019
Fasenra Symbicort Other Pulmicort
Total revenue at actual exchange rates; changes
at CER and for Q1 2021, unless stated otherwise.
16
Q4 2019
Q1 2020
Q2 2020
Q3 2020
Q4 2020
Q1 2021
Impact from stocking in Q1 2020
Comparison to ease in Q2 2021
US +8%
Symbicort (-14%); slowing market
growth. Fasenra (+30%)
Europe -15%
Symbicort (-21%) ; partial offset by
Fasenra (+25%)
EROW -22%
Japan: -26%; increasing Symbicort
competition. Fasenra (+33%)
EMS -4%
Pulmicort ($286m, -14%); continued
impact from COVID-19 and generics.
3rd generic now approved
Maintenance use with Symbicort
($165m, +3%) partly offset Pulmicort
11-2018
PBHE
PULMICORT
1 mg/2m
W
Pulmicort 1mg in 2 mL
restules
Sterle single-dose un
user uspersion
5 x 2mL
อาชนทราย ยาเฉพาะ
AstraZeneca.
Fasenra Pen 30 mg/mL
(benvallzumab
Pjection p
Symbicort
3View entire presentation